Patrick Julier

1.2k total citations
9 papers, 296 citations indexed

About

Patrick Julier is a scholar working on Oncology, Pharmacology and Genetics. According to data from OpenAlex, Patrick Julier has authored 9 papers receiving a total of 296 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Pharmacology and 3 papers in Genetics. Recurrent topics in Patrick Julier's work include Inflammatory mediators and NSAID effects (3 papers), Cancer, Stress, Anesthesia, and Immune Response (3 papers) and Estrogen and related hormone effects (2 papers). Patrick Julier is often cited by papers focused on Inflammatory mediators and NSAID effects (3 papers), Cancer, Stress, Anesthesia, and Immune Response (3 papers) and Estrogen and related hormone effects (2 papers). Patrick Julier collaborates with scholars based in United Kingdom, Australia and United States. Patrick Julier's co-authors include Janet Dunn, Rachel Midgley, M. J. S. Langman, Christopher C. McConkey, Elaine Johnstone, Rachel Kerr, David J. Kerr, Andrew Stanley, Ian Tomlinson and Francesco Pezzella and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Patrick Julier

9 papers receiving 294 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick Julier United Kingdom	6	158	87	70	68	52	9	296
Yoko Yanagisawa United Kingdom	6	167 1.1×	82 0.9×	58 0.8×	100 1.5×	39 0.8×	6	285
Nicholas Armitage United Kingdom	7	201 1.3×	120 1.4×	85 1.2×	93 1.4×	103 2.0×	12	530
C. Wei United States	5	135 0.9×	49 0.6×	128 1.8×	38 0.6×	24 0.5×	8	305
Lynn Adams United States	8	209 1.3×	46 0.5×	95 1.4×	36 0.5×	52 1.0×	9	376
Katsunori Tauchi Japan	11	118 0.7×	54 0.6×	65 0.9×	56 0.8×	114 2.2×	47	406
Włodzimierz Kupis Poland	8	87 0.6×	37 0.4×	144 2.1×	161 2.4×	31 0.6×	30	328
Angela Sacco Italy	9	157 1.0×	121 1.4×	30 0.4×	99 1.5×	32 0.6×	10	350
Hikota Hayashi Japan	11	171 1.1×	57 0.7×	126 1.8×	83 1.2×	164 3.2×	25	421
Okhee Suh United States	7	177 1.1×	177 2.0×	65 0.9×	114 1.7×	69 1.3×	9	409

Countries citing papers authored by Patrick Julier

Since Specialization

Citations

This map shows the geographic impact of Patrick Julier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Julier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Julier more than expected).

Fields of papers citing papers by Patrick Julier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Julier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Julier. The network helps show where Patrick Julier may publish in the future.

Co-authorship network of co-authors of Patrick Julier

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Julier. A scholar is included among the top collaborators of Patrick Julier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Julier. Patrick Julier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Abhishek, Abhishek, Áine McKnight, Laura C. Coates, et al.. (2022). Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study). BMJ Open. 12(5). e062599–e062599. 1 indexed citations

Kerr, Rachel, Sharon Love, Eva Segelov, et al.. (2016). Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. The Lancet Oncology. 17(11). 1543–1557. 95 indexed citations

Midgley, Rachel, Susan Love, Ian Tomlinson, et al.. (2014). Final Results from Quasar2, a Multicentre, International Randomised Phase III Trial of Capecitabine (Cap) +/- Bevacizumab (Bev) in the Adjuvant Setting of Stage Ii/Iii Colorectal Cancer (Crc). Annals of Oncology. 25. v1–v1. 6 indexed citations

Dutton, Susan, Jane Blazeby, Russell Petty, et al.. (2013). Patient-reported outcomes from a phase III multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy: Cancer Oesophagus Gefitinib (COG).. Journal of Clinical Oncology. 31(4_suppl). 6–6. 4 indexed citations

Nicum, Shibani, Claire Brooks, Rose Wharton, et al.. (2013). Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors.. Journal of Clinical Oncology. 31(15_suppl). TPS5615–TPS5615. 1 indexed citations

Ferry, D., Wasat Mansoor, J N Thompson, et al.. (2012). Phase III Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial of Gefitinib versus Placebo in Esophageal Cancer Progressing after Chemotherapy, COG (Cancer Oesophagus Gefitinib). Annals of Oncology. 23. ixe12–ixe12. 13 indexed citations

Midgley, Rachel, Christopher C. McConkey, Elaine Johnstone, et al.. (2010). Phase III Randomized Trial Assessing Rofecoxib in the Adjuvant Setting of Colorectal Cancer: Final Results of the VICTOR Trial. Journal of Clinical Oncology. 28(30). 4575–4580. 67 indexed citations

McConkey, C., M J Langman, J L Smith, et al.. (2008). VICTOR: A PHASE III PLACEBO-CONTROLLED TRIAL OF ROFECOXIB IN COLORECTAL CANCER PATIENTS FOLLOWING SURGICAL RESECTION. Annals of Oncology. 19. 1–1. 14 indexed citations

Kerr, David J., Janet Dunn, M. J. S. Langman, et al.. (2007). Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer. New England Journal of Medicine. 357(4). 360–369. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact